Susceptibility mutation for breast and ovarian cancer |
| OF THE PREFERRED EMBODIMENTS The present invention is based on the discovery of a two base pair ... |
|
Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| The present invention provides a herpetic virus selected from the group consisting of neurotrophic ... |
|
Attachment enhanced 293 cells |
| In one aspect, the invention provides improved HEK 293 cells, which cells are 293 cells which have ... |
|
Method for the production of polypeptides |
| The above identified purpose is achieved with the method according to the present invention which ... |
|
DNA sequences coding for a protein conferring male sterility |
| Thus, in a first aspect the present invention provides recombinant or isolated Nucleic acid which: ... |
|
Tumor associated nucleic acids and uses therefor |
| OF THE INVENTION The examples which follow show the isolation of nucleic acid molecules which code ... |
|
Mad-related genes in the human |
| It is an object of the invention to provide a cDNA of the human Smad2 gene. It is another object of ... |
|
Tumor associated nucleic acids and uses therefor |
| OF THE INVENTION The examples which follow show the isolation of nucleic acid molecules which code ... |
|
|
Immunoliposomes that optimize internalization into target cells
| Details |
Inventors: Benz, Christopher C.; Papahadjopoulos, Demetrois; Park, John W.; Hong, Keelung; Kirpotin, Dmitri;
Assignee: The Regents of the University of California (Oakland, CA)
Primary Examiner: Yaen; Christopher
Assistant Examiner:
Attorney, Agent or Firm: Townsend and Townsend and Crew LLP
The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab' domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides for growth-inhibiting immunoliposomes that lack growth-inhibiting therapeutic agents and yet are capable of inhibiting the growth and proliferation of target cells. |
|
DETAILED DESCRIPTION The present invention provides novel immunoliposomes optimized for delivering therapeutic agents to the cytoplasm of a target cell. These immunoliposomes exhibit increased half-life in blood, are capable of specifically targeting particular cells, and are capable of being internalized into the cytoplasm by the target cells thereby avoiding loss of the therapeutic agents or degradation by the endolysosomal pathway. Thus, in one preferred embodiment this invention provides for immunoliposomes that optimize internalization of a therapeutic agent into the cytoplasm of a cell bearing a characteristic cell surface marker. These immunoliposomes comprise an Fab' domain of an antibody wherein the Fab' domain specifically binds the characteristic marker, an amphipathic vesicle-forming lipid that forms a liposome, a polyethylene glycol derivatized lipid wherein the polyethylene glycol has an average molecular weight of between about 750 D and 5000 D, more preferably between about 1200 D and about 3000 D, most preferably about 1900 D, and a therapeutic agent contained within the liposome. The derivatized lipid is present at up to about 1. 2 mole percent, more preferably at up to about 2. 4 mole percent, and most preferably at up to about 3. 6 mole percent of total lipid. Preferred characteristic markers include growth factor receptors. Particularly preferred are growth factor receptors including HER1, HER2, HER3 and HER4 with HER2 being most preferred. The Fab' domain may be a humanized Fab' domain, more specifically a humanized Fab' domain of an anti-HER2 monoclonal antibody. The growth-inhibiting immunoliposome may further comprise a maleimide-derivatized phosphatidylethanolamine (M-PE) which forms a thioether linkage to the Fab' domain of an antibody. The vesicle forming lipid may include a phospholipid, a glycolipid, a sphingolipid, or a sterol. The immunoliposomes have an average diameter that ranges from about 50 nm to about 500 nm, more preferably about 75 nm to about 300 nm and most preferably is about 100 nm
|
| Related patents |
|
|
Virus-like particles for the induction of autoantibodies
The inventors have discovered compositions and methods of increasing the titers of antibodies to tolerogens (e.g., self antigens and foreign antigens) over those titers ...
|
|
|
Ferritin analogs
Despite the fact that ferritin is extremely selective in accumulating, storing and dispensing iron in living things, I have discovered that the forgoing objectives can ...
|
|
|
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
What is claimed is: 1. A method for the treatment of a tumor in a mammal, comprising the steps of (i) identifying said tumor as being characterized by overexpression of ...
|
|
|
Methods for diagnosing early Lyme disease
This invention is based upon the discovery that sera from patients with early Lyme disease contain predominant IgM reactivity to a major 23 kDa protein (p23; also ...
|
|
|
Tango 243 polypeptides and uses thereof
The present invention is based, at least in part, on the discovery of cDNA molecules which encode the TANGO 228, 240, and 243 proteins, all of which are either wholly ...
|
|
|
Dermatophagoides proteins and fragments thereof
What is claimed is: 1. An isolated protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:18 and SEQ ID NO:21. 2. A ...
|
|
|
Tuberculin active proteins and peptides from the cells of tubercle bacilli
What is claimed is: 1. A tuberculin active simple protein from Mycobacterium tuberculosis strain Aoyama B which is characterized by the following amino acid sequence: ##E...
|
|
|
Therapy for injured muscles
We claim: 1. A method for treating an injured muscle, the method comprising the step of local administration of a therapeutically effective amount of a botulinum toxin ...
|
|
|
Secreted and transmembrane polypeptides and nucleic acids encoding the same
1. PRO1560 A cDNA clone (DNA19902-1669) has been identified that encodes a novel polypeptide believed to be a novel member of the tetraspan family, designated in the ...
|
|
|
HIV-specific cytotoxic T-cell responses
OF INVENTION The inventors have found that two nanomer peptides, designated CLP-177 (SEQ ID NO:2) and CLP-72 (SEQ ID NO:8), a hexamer designated CLP-178 (SEQ ID NO:3), ...
|
|
|